Patents by Inventor Tobias NOLDEN

Tobias NOLDEN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240033336
    Abstract: The present invention relates to tumor antigens encoded in a 5?-upstream open reading frame (uORF) within the 5? UTR of different mRNAs. Compositions and peptides comprising such tumor antigens and a virus encoding such tumor antigens are provided. The present invention also relates to the use of such compositions, peptides and viruses in the treatment of cancer.
    Type: Application
    Filed: March 15, 2023
    Publication date: February 1, 2024
    Inventors: Elodie BELNOUE, Madiha DEROUAZI, Paul ADAM, Imgard Rita Maria HOFMANN, Ralf LEONHARDT, Samuel LUKOWSKI, Tobias NOLDEN, Francesca TRAPANI
  • Publication number: 20230183650
    Abstract: The present invention relates to a method for rescue of Vesicular Stomatitis Virus (VSV) from DNA in a HEK293 cell line or a HEK293 cell line adapted to suspension growth comprising (a) providing cells from a HEK293 cell line or a HEK293 cell line adapted to suspension growth in cell culture, (b) transfecting the cells with at least one plasmid, wherein the at least one plasmid comprises (i) an expression cassette comprising a VSV genomic cDNA; (ii) at least one expression cassette encoding VSV nucleoprotein (N) protein, VSV phosphoprotein (P) protein, and VSV large (L) protein; and (iii) an expression cassette encoding SV40 Large T antigen; (c) culturing the transfected cells; and (d) harvesting the cell culture supernatant comprising the rescued VSV.
    Type: Application
    Filed: July 8, 2022
    Publication date: June 15, 2023
    Applicant: Boehringer Ingelheim International GmbH
    Inventor: Tobias Nolden
  • Publication number: 20220010334
    Abstract: The present invention relates to VSV chimeric vectors, characterized in that the vectors comprise a gene coding for a glycoprotein GP of the Dandenong virus (DANDV) or Mopeia vims (MOPV) and lack a functional gene coding for envelope protein G of the VSV. The invention also provides VSV chimeric vector systems. In addition, the invention relates to uses of the VSV chimeric vectors and systems of the invention, including the use in medicine such as in the treatment of solid tumors.
    Type: Application
    Filed: November 22, 2019
    Publication date: January 13, 2022
    Applicants: Vira Therapeutics GmbH, Boehringer Ingelheim International GmbH
    Inventors: Tobias NOLDEN, Patrik ERLMANN, Guido WOLLMANN, Zoltan BANKI, Bart SPIESSCHAERT, Janine KIMPEL, Dorothee VON LAER